Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

terminated375%
completed125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00044291
terminatedphase_3

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00010322
terminatedphase_3

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

NCT00267553
terminatedphase_3

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

NCT00097344

Clinical Trials (4)

Showing 4 of 4 trials
NCT00044291Phase 3

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Completed
NCT00010322Phase 3

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

Terminated
NCT00267553Phase 3

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Terminated
NCT00097344Phase 3

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4